ADPT — Adaptive Biotechnologies Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1478320 ·
Last close
$29.43
Market Cap
$4.70B
52W High
$29.96
52W Low
$12.00
ADV30
2,092,460
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 70,874,000 | 52,166,000 | -19,206,000 | -20,033,000 | 505,943,000 | 77,581,000 | 281,702,000 |
| Dec 2025 | 71,681,000 | 53,457,000 | -12,773,000 | -13,579,000 | 512,736,000 | 70,495,000 | 287,735,000 |
| Sep 2025 | 93,973,000 | 75,816,000 | 10,290,000 | 9,546,000 | 490,610,000 | 55,034,000 | 286,357,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,039,000
Investing CF
$21,520,000
Financing CF
$32,452,000
CapEx
$-2,496,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.41
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,383,356,000
Inventory
$11,206,000
Receivables
$48,315,000
ST Investments
$140,753,000
EBIT TTM
$-37,880,000
Pretax Income TTM
$-49,642,000
Interest Exp TTM
$11,762,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$308,080,992
EBITDA
$-21,327,000
Free Cash Flow
$18,976,624
Enterprise Value
$3,936,211,456
Total Cash
$344,255,008
Total Debt
$410,499,008
Shares Out
159,595,842
Trailing EPS
$-0.40
Book Value
$0.90
ROE
-38.8%
ROA
-4.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 276,976,000 | -57,123,000 | -59,499,000 | 512,736,000 | 287,735,000 | 218,793,000 | -45,986,000 |
| Dec 2024 | 178,957,000 | -155,344,000 | -159,492,000 | 539,376,000 | 336,891,000 | 202,709,000 | -95,212,000 |
| Dec 2023 | 170,276,000 | -201,606,000 | -225,250,000 | 661,134,000 | 352,856,000 | 308,399,000 | -156,324,000 |
| Dec 2022 | 185,308,000 | -200,186,000 | -200,191,000 | 856,617,000 | 392,519,000 | 464,165,000 | -183,945,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.18
Max Pain — expiry 2027-01-15
max pain strike: $15.00 · spot: $28.74 · call oi: 2,404 · put oi: 120
Expected Move to 2027-01-15:
±$8.55
(29.75%) —
implied range
$20.19 –
$37.29
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $4.98B | $11.00 | — |
| CRSP | CRISPR Therapeutics AG | $5.24B | $54.23 | — |
| RLAY | Relay Therapeutics, Inc. | $3.83B | $17.47 | — |
| SRRK | Scholar Rock Holding Corp | $5.92B | $48.63 | — |
| CGON | CG Oncology, Inc. | $5.95B | $67.15 | — |
News headlines (Yahoo Finance, 1h cache)
Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update
2026-09-25 21:06 · Yahoo
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure
2026-09-25 12:03 · Yahoo
NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)
2026-09-24 11:12 · Yahoo
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?
2026-09-23 00:28 · Yahoo
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®
2026-09-17 12:00 · Yahoo
Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.
2026-08-21 14:55 · Yahoo
Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...
2026-07-30 05:03 · Yahoo
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
2026-07-29 23:00 · Yahoo
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
2026-07-29 22:25 · Yahoo
Adaptive Biotechnologies Q2 Earnings Call Highlights
2026-07-29 22:03 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.